JNJ Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 21.47% compared to Johnson & Johnson's net margin of 39.21%. Johnson & Johnson's return on equity of 33.27% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Johnson & Johnson has a consensus price target of $209.29, signalling upside risk potential of 1.71%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 5.74%. Given that Gilead Sciences, Inc. has higher upside potential than Johnson & Johnson, analysts believe Gilead Sciences, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.357, which suggesting that the stock is 64.296% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.5%. Gilead Sciences, Inc. offers a yield of 2.52% to investors and pays a quarterly dividend of $0.79 per share. Johnson & Johnson pays 84.8% of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.

Johnson & Johnson quarterly revenues are $24B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.8B. Johnson & Johnson's net income of $5.2B is higher than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Johnson & Johnson's price-to-earnings ratio is 19.86x while Gilead Sciences, Inc.'s PE ratio is 19.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.41x versus 5.42x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 21.47% compared to Johnson & Johnson's net margin of 31.72%. Johnson & Johnson's return on equity of 33.27% beat Eli Lilly & Co.'s return on equity of 106.26%.

Johnson & Johnson has a consensus price target of $209.29, signalling upside risk potential of 1.71%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.01%. Given that Eli Lilly & Co. has higher upside potential than Johnson & Johnson, analysts believe Eli Lilly & Co. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.357, which suggesting that the stock is 64.296% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.5%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Johnson & Johnson pays 84.8% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24B, which are larger than Eli Lilly & Co. quarterly revenues of $17.6B. Johnson & Johnson's net income of $5.2B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Johnson & Johnson's price-to-earnings ratio is 19.86x while Eli Lilly & Co.'s PE ratio is 53.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.41x versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics, Inc. has a net margin of 21.47% compared to Johnson & Johnson's net margin of -834.87%. Johnson & Johnson's return on equity of 33.27% beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.

Johnson & Johnson has a consensus price target of $209.29, signalling upside risk potential of 1.71%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $94.50 which suggests that it could grow by 6.5%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Protagonist Therapeutics, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.357, which suggesting that the stock is 64.296% less volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.192, suggesting its more volatile than the S&P 500 by 119.221%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.5%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.8% of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24B, which are larger than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. Johnson & Johnson's net income of $5.2B is higher than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, Johnson & Johnson's price-to-earnings ratio is 19.86x while Protagonist Therapeutics, Inc.'s PE ratio is 140.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.41x versus 27.21x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 21.47% compared to Johnson & Johnson's net margin of 38.89%. Johnson & Johnson's return on equity of 33.27% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Johnson & Johnson has a consensus price target of $209.29, signalling upside risk potential of 1.71%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 0.6%. Given that Johnson & Johnson has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Johnson & Johnson is more attractive than Regeneron Pharmaceuticals, Inc..

Johnson & Johnson has a beta of 0.357, which suggesting that the stock is 64.296% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.5%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Johnson & Johnson pays 84.8% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Johnson & Johnson's net income of $5.2B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Johnson & Johnson's price-to-earnings ratio is 19.86x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.41x versus 6.07x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.